Clinical Trial Update: XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for XS-03 in combination with FOLFOX or FOLFIRI and bevacizumab for metastatic colorectal cancer with RAS mutation, in Phase 1/Phase 2 and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Colorectal Cancer with Ras Mutation

Drugs mentioned

• Bevacizumab (bevacizumab)
• XS-03

Snippet

Sponsor: NovaOnco Therapeutics Co., Ltd. | Conditions: Colorectal Cancer, Metastatic Colorectal Cancer With RAS Mutation | Phase 1, Phase 2 | Status: ENROLLING_BY_INVITATION